Cadherins as Cancer Biomarkers
AssigneeThe General Hospital Corporation
InventorsShyamala Maheswaran, David Tsai Ting, Daniel A. Haber
Life of this patent
Estimating the term…
Abstract
Methods of isolating, enriching, capturing, identifying, or detecting the presence of, cancerous cells in a sample, e.g., a blood sample from a subject, by detecting the presence of one or more cancer cell surface markers selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), and optionally an additional cancer cell surface marker, e.g., EpCAM, MUC1, EphB4, EGFR, CEA, and/or HER2.
Claims25
A method of detecting the presence of a circulating tumor cell (CTC) in a sample from a subject, the method comprising:
- providing a sample comprising blood from a subject;
- and
- contacting the sample with one or more agents that bind to a cancer cell surface marker selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13);
- and
- detecting the binding of the agent to a cancer cell surface marker present on a cell in the sample;
- thereby detecting the presence of a cancer cell in the sample.
A method of diagnosing cancer in a subject, the method comprising:
- providing a sample comprising blood from the subject;
- and
- contacting the sample with one or more agents that bind to a cancer cell surface marker selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), under conditions sufficient to allow binding of the agent to cells expressing the surface marker;
- and
- detecting the binding of the agent to a cancer cell surface marker present on a cell in the sample;
- wherein the presence of binding to a cell in the sample indicates that the subject has cancer.
(canceled)
(canceled)
(canceled)
A device for separation of cells in a sample, the device comprising an inlet, and outlet, and one or more areas coated with an agent that binds a cancer cell surface marker selected from the group consisting of cadherin 1 (CDH1), CDH2, CDH3, CDH4, CDH5, CDH9, CDH11, CDH17, CDH19, protocadherin 9 (PCDH9) and/or PCDH beta 13 (PCDHb13), configured to separate cells that express the cancer cell surface marker from cells that do not express the cancer cell surface marker.
(canceled)
(canceled)
Dependencies are inferred from the claim text.